Video

Dr. Singh Discusses the Next Steps for Immunotherapy in GISTs

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the next steps following a trial investigating single-agent and combination immunotherapy for patients with gastrointestinal stromal tumors (GIST).

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the next steps following a trial investigating single-agent and combination immunotherapy for patients with gastrointestinal stromal tumors (GIST).

This phase II trial examined the role of single-agent nivolumab (Opdivo) versus nivolumab plus ipilimumab (Yervoy). Currently, 14 patients have been enrolled on the study and 8 remain on treatment. Stable disease was the best response in 3 of 7 patients treated with nivolumab monotherapy and 1 partial response and 2 patients with stable disease were reported for the nivolumab/ipilimumab arm.

One-third of patients have received benefit, not just in terms of disease shrinkage but a prolonged disease control, which is important for the group, says Singh. The real question is why those patients are receiving benefit. In a separate ongoing study, physicians are looking at predictive biomarkers to try to identify who is responding, why they are responding, or reasons why patients do not respond to immunotherapy.

Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS